Pluri Inc. (PLUR)

NCM – Цена в реальном времени. Валюта: USD

2.03

-0.05 (-2.34%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

2.00

-0.03 (-1.54%)

После закрытия: Jun 26, 2026, 6:37 PM EDT

16.06.2026

Plurilock Announces Results of Annual General Meeting

Vancouver, British Columbia--(Newsfile Corp. - June 16, 2026) - Plurilock Security Inc. (TSXV: PLUR) (OTCQB: PLCKF) ("Plurilock" or the "Company"), a services-led, product-enabled, AI-native cybersecurity company, is pleased to announce the results of its Annual General Meeting (the "Meeting") of shareholders held on June 16, 2026. All resolutions presented to the shareholders were approved.

02.06.2026

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Two regenerative aesthetic and longevity products, with clinically validated ingredients , are expected to reach the U.S. market during 2026, entering a rapidly expanding U.S. medical aesthetics market, projected to reach $90 billion by 2030 HAIFA, Israel, June 02, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ: PLUR) (TASE: PLUR), a biotechnology company pioneering 3D cell-expansion technology to power scalable cell-based products across therapeutics, regenerative aesthetics, longevity and agri-food tech, today announced that its consumer-health and aesthetics subsidiary, Cellav Health and Aesthetics Ltd. (“Cellav”), has completed the development and U.S. cosmetic product listings of two flagship regenerative aesthetic products - Regenativo+ and Placento+, clearing the path for commercial launch in the United States.

22.12.2025

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

HAIFA, Israel, Dec. 22, 2025 (GLOBE NEWSWIRE) -- Pluri, Inc. (“Pluri”, the “Company”, “we” or “us”) (Nasdaq, TASE: PLUR), a leading biotechnology company leveraging its proprietary platform for cell-based solutions through a collaborative network of ventures, today announced expansion of its manufacturing agreement signed in 2024 with Remedy Cell Ltd. (“Remedy Cell”), an innovative biopharmaceutical company developing stem cell-derived, cell-free therapeutics for complex fibrotic conditions.

27.11.2025

Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript

Plurilock Security Inc. ( PLUR:CA ) Q3 2025 Earnings Call November 27, 2025 11:00 AM EST Company Participants Ian Paterson - CEO & Director Scott Meyers - CFO & Corporate Secretary Conference Call Participants Ryan Freemantle Presentation Ryan Freemantle Good morning, and thank you for joining us for Plurilock Securities conference call to discuss its financial results for the quarter ending September 30, 2025. I'm Ryan Freemantle from Sophic Capital, and we handle Plurilock's Investor Relations.

Видео

No Data

There is no data to display

Пресс-релизы

16.06.2026

Plurilock Announces Results of Annual General Meeting

02.06.2026

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

22.12.2025

Pluri Inc. (PLUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pluri Inc. (PLUR)

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Search stocks

Pluri Inc. (PLUR)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Pluri Inc. (PLUR)

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved

Plurilock Security Inc. (PLUR:CA) Q3 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

Plurilock Announces Results of Annual General Meeting

Pluri Advances Toward U.S. Commercial Launch Through Its Subsidiary Cellav, Following Completion of Regenerative Aesthetic Products Listing

Pluri and Remedy Cell Expand Collaboration; Successful Engineering Runs and Clinical-Grade Manufacturing Achieved